Le Lézard
Classified in: Health
Subjects: PDT, FDA

Fewer Leads, Fewer Complications: BIOTRONIK US Launches Proven DX Technology for Heart Failure Patients



LAKE OSWEGO, Ore., July 19, 2017 /PRNewswire/ -- BIOTRONIK today announced FDA approval and availability of the Intica DX and Intica cardiac resynchronization therapy (CRT)-DX implantable cardioverter defibrillator (ICD) systems. The launch of Intica CRT-DX extends the proven benefits of BIOTRONIK's DX technology to heart failure patients. DX eliminates the need for an atrial lead while still providing physicians with critical diagnostic information based on a true atrial signal.

The launch of Intica CRT-DX extends the proven benefits of BIOTRONIK's DX technology to heart failure patients, which eliminates the need for an atrial lead while still providing critical diagnostic information.

BIOTRONIK launched DX technology in 2013 with a focus on improving patient care and decreasing the rate of complication. DX minimizes hardware and provides critical diagnostics that allow physicians to better monitor, manage and prevent cardiac events. Intica CRT-DX is the first cardiac rhythm management device for the treatment of heart failure patients that delivers atrial diagnostics without an atrial lead. Atrial diagnostics aid physicians in the early identification of supraventricular tachycardia (SVT), atrial fibrillation (AF) and atrial ventricular synchronization.

"When treating heart failure patients, we are often managing several comorbidities that can increase the likelihood of complications and risk when implanting a CRT-D and in the years that follow," said Dr. Larry Chinitz, a cardiac electrophysiologist in New York City. "Balancing risk and therapeutic needs has historically been a challenge. CRT-DX changes this and creates a higher echelon of patient care. Now there is an ICD for heart failure patients that minimizes hardware and risk while providing optimal diagnostics to help patients feel better and stay out of the hospital. The addition of DX technology to a CRT device is a breakthrough."

Intica CRT-DX also includes BIOTRONIK's recently FDA approved MultiPole Pacing (MPP) technology. MPP enables the left ventricle (LV) to be paced twice per cardiac cycle?sequentially or simultaneously?allowing for even greater customization of heart failure therapy.

Only BIOTRONIK offers MR conditional devices with independent, simultaneous LV paces.

"BIOTRONIK is disrupting the status quo and setting a new standard of care as we continue to introduce innovations that help hospitals improve outcomes, lower readmissions and take patient care to a new level," said Marlou Janssen, President of BIOTRONIK, Inc. "Our DX technology is standalone in an industry that knows the rate of complication increases with more leads. Doctors trust and rely on our DX technology because it delivers?less hardware, less complications, paramount diagnostics. We know that the impact of DX is profound for patients and that is why we invested in bringing Intica CRT-DX to market."

The Intica DX device systems also incorporate other industry-leading technologies including:

References
1 Hindricks, G., Taborsky, M., Glikson, M., Heinrich, U., Schumacher, B., Katz, A., Søgaard, P. (2014). Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): A randomised controlled trial. The Lancet, 583-590.

2 Hindricks G et al. European Heart Journal. 2017, May 10. doi: https://doi.org/10.1093/eurheartj/ehx015

About BIOTRONIK
A global leader in cardio- and endovascular medical technology, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including Magmaris®*, the first clinically-proven resorbable magnesium scaffold; BIOTRONIK Home Monitoring®; Pulsar®-18, the world's first 4F compatible stent for treating long lesions; Orsiro®**, the ultrathin 60 micron drug-eluting stent; and the world's first implantable cardioverter defibrillators and heart failure therapy devices with ProMRI® technology.

* Not currently available in the United States.
** CAUTION ? Investigational device. Limited by United States law to investigational use.

For more information, visit: www.biotronik.com 
Twitter: @BIOTRONIK_US 
Facebook: facebook.com/BIOTRONIKUS
LinkedIn: linkedin.com/company/BIOTRONIK
YouTube: youtube.com/channel/UC3d_gUXhUICD-mxHRYDoHcQ

BIOTRONIK is a leader in cardio- and endovascular medical technology. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. (PRNewsFoto/BIOTRONIK)

SOURCE BIOTRONIK


These press releases may also interest you

at 01:00
LEIDEN, The Netherlands, October 23, 2017 /PRNewswire/ -- Net result is a reduction of the fully diluted share capital by 8,212,468 shares  Total number of shares issued in warrant exercises, option exercises and bond conversions since the...

at 00:01
VANCOUVER, Oct 23, 2017 /CNW/ - More than 2,500 heart health experts from across Canada and around the globe meet again in Vancouver today for the Canadian Cardiovascular Congress. Experts at all stages of their careers collaborate, share new ideas,...

22 oct 2017
LAGUNA NIGUEL, Calif., Oct. 22, 2017 /PRNewswire/ -- The management team of Crestavilla, a luxury senior living community currently under construction in Laguna Niguel, Calif., has launched a Halloween costume drive to benefit the boys and girls who...

22 oct 2017
OTTAWA, Oct. 20, 2017 /CNW/ - The Honourable Ginette Petitpas Taylor, Minister of Health, will deliver remarks at the Kid Food Nation Gala and present awards to the winners of the national recipe contest. The Minister will be available to answer...

22 oct 2017
LONDON, October 22, 2017 /PRNewswire/ -- ? The Dermalex skincare survey indicates that as much as  50% of the GB adult population have suffered with skin conditions in their life ? 64% have had eczema, psoriasis, rosacea or acne for over a decade...

22 oct 2017
PHILADELPHIA, Oct. 22, 2017 /PRNewswire-USNewswire/ -- Today, Abby and Erin Delaney are able to sit independently from one another, be held separately in their mother and father's arms, and can practice rolling over and crawling. Such everyday...




News published on 19 july 2017 at 10:30 and distributed by: